HomeMarketJefferies rai...

Jefferies raised the price target for the Celldex Therapeutics Inc. (NASDAQ:CLDX) stock to “”a Buy””

Jefferies raised the price target for the Celldex Therapeutics Inc. (NASDAQ:CLDX) stock to “a Buy”. The rating was released on September 17, 2021, according to finviz. The research report from Guggenheim has initiated the stock to Buy, with a price target set at $66. The stock was initiated by Cantor Fitzgerald, who disclosed in a research note on February 21, 2020, to Overweight and set the price objective to $8. In their research brief published August 01, 2017, H.C. Wainwright analysts resumed the Celldex Therapeutics Inc. stock to Buy with a price target of $10.

The latest trade, Performances and Moving Averages give us the following Picture

The share price of Celldex Therapeutics Inc. (NASDAQ:CLDX) dipped -1.62% to close Friday’s market session at $41.84, lower as compared to yesterday’s close. The stock price fluctuated between $40.75 and $42.355 throughout the trading session with the volume trading being 741180 shares, which represented a significant variation when compared to the three months average volume of 423.10K shares. The firm’s stock price fluctuated 0.10% within the last five trades and -2.43% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price increased 38.04% in the last 6 months and 3.95% was added to its value over the previous 3 months. CLDX stock is trading at a margin of -3.97%, -5.93% and 19.29% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.

Do You Know The Best Place To Find Gains In Volatile Markets?

In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.

Click here for full details and to join for free.


As of the close of trading, CLDX deals in the Healthcare domain. The stock is trading -13.55 percent below its 52-week high and 110.78 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is 25.51. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.

What Does Celldex Therapeutics Inc.’s Profitability and Valuation Ratios Tell Us About the Stock?

The stock’s market cap achieved a total value of $2.09 billion as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. Forward price-to-earnings is calculated using predicted earnings for the next financial year’s P/E determination. The stock has achieved an effective Price-to-Sales Ratio of 870.27 that mirrors the cost to be found for sales by the market. The firm managed a Price-to-Book ratio of 6.05, which equates the market value of a stock with its book value.

Is Insider Trading a Real Thing?

KELER TIBOR, the EXECUTIVE VP & CSO at Celldex Therapeutics Inc. (CLDX) has sold 16,860 shares of firm on Dec 07 at a price of $36.93 against the total amount of $0.62 million. In another inside trade, Cavanaugh Sarah, SVP OF CORP AFFAIRS & ADMIN. of Celldex Therapeutics Inc. (NASDAQ:CLDX) sold 1,355 shares of the firm on Aug 18 for a total worth of $49289.0 at a price of $36.38. An inside trade which took place on Aug 17, SVP OF CORP AFFAIRS & ADMIN. of Celldex Therapeutics Inc. Cavanaugh Sarah sold 31,312 shares of firm against total price of $1.15 million at the cost of $36.73 per share.



Please enter your comment!
Please enter your name here

Recent Post